Engineering CAR T cells to secrete VEGF-neutralizing scFvs enhances antitumor activity against solid tumors
Torahito A. Gao, Ryan M. Shih, Justin D. Clubb, Shao-Hsi Hung, Tanya Singh, Laura B. James-Allan, Ga / science - Science Translational Medicine, Volume 18, Issue 839, March 2026.
AI Summary: Researchers engineered CAR‑T cells to secrete VEGF‑neutralizing single‑chain antibodies, improving infiltration and antitumor activity against solid tumors in preclinical models. By locally neutralizing VEGF, the approach remodels the tumor microenvironment and enhances CAR‑T efficacy, offering a plausible strategy to overcome the long‑standing barrier of poor CAR‑T performance in solid cancers.
Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61
Related Stories
Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128
Teclistamab outperforms standard regimens in earlier-line relapsed myeloma / 47 hrs
Common asthma drug may overcome immunotherapy resistance in cancers / 11 days
Retifanlimab plus chemotherapy extends survival in advanced squamous anal cancer / 13 days
MYC overactivity enables DNA repair and chemotherapy resistance in tumours / 13 days
Zoldonrasib shows durable responses in KRAS G12D lung cancer / 5 wks
James P. Allison wins AACR lifetime achievement award / 7 wks
Metabolic enzyme linked to immunotherapy benefit; routing metabolites may boost response / 1 month
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Weight Loss, FDA, Drug Pricing, Trump Administration and look for the RSS link.
StackHealth Time Machine